TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36972088

Group type: EXPERIMENTAL
Intervention: Discordant-positive participants (perceived health change more positive than actual)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Discordant-negative participants (perceived health change worse than actual)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Concordant participants (perceived health change aligned with actual)
Number of subjects: 0
Study: 36972105

Group type: EXPERIMENTAL
Intervention: Web-based therapist tutorial on Prolonged Grief Disorder Therapy (PGDT)
Number of subjects: 406
Study: 36972117

Group type: EXPERIMENTAL
Intervention: Ohnut (phallus length reducer)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control (no intervention)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal insert (substudy)
Number of subjects: 40
Study: 36972140

Group type: EXPERIMENTAL
Intervention: Skin-only resection (Group-S)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Skin-plus-orbicularis muscle resection (Group-M)
Number of subjects: 24
Study: 36972208

Group type: EXPERIMENTAL
Intervention: GeneXpert HIV-1 assay
Number of subjects: 242

Group type: COMPARATOR
Intervention: Central laboratory testing (standard of care)
Number of subjects: 242
Study: 36972231

Group type: EXPERIMENTAL
Intervention: Diacutaneous fibrolysis (DF)
Number of subjects: 86
Study: 36972279

Group type: EXPERIMENTAL
Intervention: Semantic-based memory-encoding strategy
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cognitive stimulation
Number of subjects: 39
Study: 36972491

Group type: EXPERIMENTAL
Intervention: R-CHOP + Bortezomib
Number of subjects: 0

Group type: COMPARATOR
Intervention: R-CHOP
Number of subjects: 0
Study: 36972639

Group type: EXPERIMENTAL
Intervention: Experimental Group 1 (tip position in subclavian or axillary vein)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Experimental Group 2 (tip position not specified)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Control Group (tip position not specified)
Number of subjects: 330
Study: 36972694

Group type: EXPERIMENTAL
Intervention: Azithromycin (20-mg/kg single oral dose)
Number of subjects: 21832

Group type: COMPARATOR
Intervention: Placebo (equivalent volume)
Number of subjects: 21832
Study: 36972738

Group type: EXPERIMENTAL
Intervention: Gel Stent
Number of subjects: 0

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 0
Study: 36972796

Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment for hepatitis C virus (HCV), specific dosage and duration not mentioned.
Number of subjects: 0
Study: 36972800

Group type: EXPERIMENTAL
Intervention: 26 g of freeze-dried wild blueberry (WBB) powder (302 mg anthocyanins)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Matched placebo (0 mg anthocyanins)
Number of subjects: 61
Study: 36972814

Group type: EXPERIMENTAL
Intervention: Endovascular intervention (EVI)
Number of subjects: 4475

Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 4475

Group type: COMPARATOR
Intervention: Hybrid surgery
Number of subjects: 4475
Study: 36972835

Group type: EXPERIMENTAL
Intervention: Digital insertion of Foley catheter balloon
Number of subjects: 100

Group type: COMPARATOR
Intervention: Speculum-guided insertion of Foley catheter balloon
Number of subjects: 100
Study: 36972920

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy with stent removal (CEASR)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Repeated carotid angioplasty and stenting (rePTA/S)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Both groups (CEASR and rePTA/S)
Number of subjects: 31
Study: 36972964

Group type: EXPERIMENTAL
Intervention: Immune and metabolic whole-blood markers in patients with sepsis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated lipidomics and RNASeq transcriptomics analyses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical phenotyping and blood culture test results
Number of subjects: 0
Study: 36972972

Group type: EXPERIMENTAL
Intervention: KDIGO-based AKI care bundle
Number of subjects: 1302

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 1302
Study: 36973007

Group type: EXPERIMENTAL
Intervention: Interventions relieving dyspnea
Number of subjects: 0
Study: 36973055

Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention (home visit from volunteers, care plan by interprofessional team)
Number of subjects: 599

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: Health TAPESTRY intervention
Number of subjects: 599
Study: 36973127

Group type: EXPERIMENTAL
Intervention: PD-ROBOSCORE (difficulty score for robotic pancreatoduodenectomy)
Number of subjects: 1184

Group type: COMPARATOR
Intervention: Robotic pancreatoduodenectomy
Number of subjects: 1184
Study: 36973578

Group type: EXPERIMENTAL
Intervention: Attribution of GWI to behavior (e.g., diet and exercise)
Number of subjects: 262

Group type: COMPARATOR
Intervention: Attribution of GWI to deployment, physical, or psychological causes
Number of subjects: 262
Study: 36973667

Group type: EXPERIMENTAL
Intervention: Standard care plus add-on person-centred care through telephone support and a digital platform
Number of subjects: 220

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 220
Study: 36973671

Group type: EXPERIMENTAL
Intervention: Quartile 4 (waist:height ratio 0.62)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Higher waist:height ratio
Number of subjects: 541
Study: 36973688

Group type: EXPERIMENTAL
Intervention: verum Electroacupuncture (vEA) - ten weekly treatment visits at 13 therapeutic acupuncture points
Number of subjects: 64

Group type: COMPARATOR
Intervention: sham Electroacupuncture (sEA) - weekly treatment visits at 7 non-disease-related acupuncture points
Number of subjects: 64
Study: 36973732

Group type: EXPERIMENTAL
Intervention: IBS women with sexual dysfunction (SxD)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: IBS women without sexual dysfunction (SxD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Controls (women without IBS)
Number of subjects: 51
Study: 36973741

Group type: EXPERIMENTAL
Intervention: golimumab + MTX
Number of subjects: 685

Group type: COMPARATOR
Intervention: golimumab without MTX
Number of subjects: 685
Study: 36973743

Group type: EXPERIMENTAL
Intervention: Proportional Assist Ventilation (PAV+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 0
Study: 36973774

Group type: EXPERIMENTAL
Intervention: Active Music Engagement (AME)
Number of subjects: 228

Group type: COMPARATOR
Intervention: Attention control condition
Number of subjects: 228
Study: 36973815

Group type: EXPERIMENTAL
Intervention: PASC (surgical patient safety checklist)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Not using PASC (due to various reasons)
Number of subjects: 428
Study: 36973954

Group type: EXPERIMENTAL
Intervention: rilonacept 320 mg followed by weekly doses of 160 mg for 6 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rilonacept
Number of subjects: 20

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study: 36974122

Group type: EXPERIMENTAL
Intervention: TBI patients
Number of subjects: 160
Study: 36974270

Group type: EXPERIMENTAL
Intervention: Use of the internet for health information and eHealth literacy
Number of subjects: 2924
Study: 36974462

Group type: EXPERIMENTAL
Intervention: Skin microbiota from high-risk patients
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Toll-like receptor 4 (TLR4) antagonists
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Gram-negative bacteria
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metagenome sequencing analyses
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Increased amino acid metabolites
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Antibiotic resistance genes
Number of subjects: 90
Study: 36974574

Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy in combination with immune checkpoint inhibitors (pembrolizumab)
Number of subjects: 27
Study: 36974638

Group type: EXPERIMENTAL
Intervention: Linagliptin and allopurinol in combination (Group 4)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Linagliptin (Group 3)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Allopurinol (Group 2)
Number of subjects: 800

Group type: COMPARATOR
Intervention: N-acetyl cysteine and saline (Control Group 1)
Number of subjects: 800
Study: 36974653

Group type: EXPERIMENTAL
Intervention: Supervised multi-nut oral food challenge (OFC) using multi-nut butter
Number of subjects: 212

Group type: COMPARATOR
Intervention: Standard care (home introduction of individual tree nuts)
Number of subjects: 212
Study: 36974680

Group type: EXPERIMENTAL
Intervention: Post-PCI angina assessment using the Seattle Angina Questionnaire (SAQ-7) and European quality of life-5 dimension-5 level (EQ-5D-5L) questionnaires.
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Intracoronary physiology assessments before and after stenting.
Number of subjects: 230
Study: 36974714

Group type: EXPERIMENTAL
Intervention: Preoperative renal insufficiency (RI) group
Number of subjects: 502281

Group type: EXPERIMENTAL
Intervention: Preoperative renal insufficiency (RI) group with current dialysis, eGFR ≤ 30 ml/min/1.73 m² or concomitant anemia
Number of subjects: 502281
Study: 36974735

Group type: EXPERIMENTAL
Intervention: DASH diet intervention
Number of subjects: 611
Study: 36974887

Group type: EXPERIMENTAL
Intervention: Postoperative measurement of highly fluorescent immature platelet fraction (H-IPF)
Number of subjects: 391
Study: 36974988

Group type: EXPERIMENTAL
Intervention: AS01-adjuvanted vaccine containing four surface proteins from non-typable
Number of subjects: 0
Study: 36975019

Group type: EXPERIMENTAL
Intervention: More intense blood pressure control
Number of subjects: 22885

Group type: COMPARATOR
Intervention: Usual care or no intervention on blood pressure (placebo)
Number of subjects: 22885

Group type: EXPERIMENTAL
Intervention: Antihypertensive agents
Number of subjects: 22885

Group type: EXPERIMENTAL
Intervention: Intense blood pressure control
Number of subjects: 22885
Study: 36975201

Group type: EXPERIMENTAL
Intervention: Gene therapy (GT) for SCD
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Knowledge about GT
Number of subjects: 104
Study: 36975207

Group type: EXPERIMENTAL
Intervention: Third dose of mRNA COVID-19 vaccine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Fourth dose of mRNA COVID-19 vaccine
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Booster doses (third and fourth doses)
Number of subjects: 106
Study: 36975308

Group type: EXPERIMENTAL
Intervention: Urinary (TIMP-2) × (IGFBP7)
Number of subjects: 300
Study: 36975369

Group type: EXPERIMENTAL
Intervention: V160 vaccine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 36975790

Group type: EXPERIMENTAL
Intervention: Nifurtimox 60-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifurtimox 30-day regimen (10 to 20 mg/kg/day for patients aged <12 years and body weight <40 kg; 8 to 10 mg/kg/day for those aged ≥12 years and body weight ≥40 kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Historical placebo control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nifurtimox (both regimens)
Number of subjects: 0
Study: 36976258

Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) supplementation
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 622

Group type: EXPERIMENTAL
Intervention: Combined FA and Creatine supplementation
Number of subjects: 622

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 622
Study: 36976326

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (IVES), performed 3 days a week for 8 weeks, 24 sessions, 20 minutes each
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Intravaginal electrical stimulation (IVES)
Number of subjects: 48
Study: 36976619

Group type: EXPERIMENTAL
Intervention: SteWARdS Antibiotic Defence app
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 400
Study: 36976624

Group type: EXPERIMENTAL
Intervention: TelePhys group (monthly telemedicine consultation focusing on physical activity coaching)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: TeleDiet group (monthly telemedicine consultation involving diet coaching)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Both groups (TelePhys and TeleDiet)
Number of subjects: 90
Study: 36976630

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention administered by trained nurses, details on dosage and duration not specified.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) intervention with caregiver participation, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Motivational Interviewing (MI) intervention administered only to individual patients, details on dosage and duration not specified.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving standard care without MI, details on dosage and duration not specified.
Number of subjects: 0
Study: 36976651

Group type: EXPERIMENTAL
Intervention: Elexacaftor/tezacaftor/ivacaftor (ETI)
Number of subjects: 236
Study: 36976655

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 screening
Number of subjects: 0
Study: 36977289

Group type: EXPERIMENTAL
Intervention: Ficlatuzumab with Cetuximab
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ficlatuzumab Monotherapy
Number of subjects: 60
Study: 36977292

Group type: EXPERIMENTAL
Intervention: Breast-conserving therapy (BCT) including lumpectomies with negative margins followed by whole breast radiation with boost to all lumpectomy beds.
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Preoperative MRI (n = 189)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: No preoperative MRI (n = 15)
Number of subjects: 204
Study: 36977327

Group type: EXPERIMENTAL
Intervention: Epiretinal membrane
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Myopic retinoschisis
Number of subjects: 610

Group type: EXPERIMENTAL
Intervention: Macular hole
Number of subjects: 610
Study: 36977371

Group type: EXPERIMENTAL
Intervention: AMSA-guided CPR
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard CPR
Number of subjects: 31
Study: 36977536

Group type: EXPERIMENTAL
Intervention: Mobile application ACP programme and a 30 min interview with a trained intervention provider
Number of subjects: 264

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 264
Study: 36977629

Group type: EXPERIMENTAL
Intervention: Ecological momentary assessment (EMA) on irritability-related constructs and other mood and anxiety symptoms three times a day for 7 days.
Number of subjects: 152
Study: 36977960

Group type: EXPERIMENTAL
Intervention: Ritlecitinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Statistical and POPPK simulation approaches
Number of subjects: 0
Study: 36977972

Group type: EXPERIMENTAL
Intervention: Biomimetic polyurethane-based scaffold
Number of subjects: 15
Study: 36977973

Group type: EXPERIMENTAL
Intervention: Amcenestrant 400 mg QD
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Amcenestrant 300 mg BID
Number of subjects: 10
Study: 36977981

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 206

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 206
Study: 36978026

Group type: EXPERIMENTAL
Intervention: schiZotypy Autism Questionnaire (ZAQ)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Clinical diagnoses from interdisciplinary teams at specialised psychiatric clinics
Number of subjects: 500
Study: 36978035

Group type: EXPERIMENTAL
Intervention: EDP plus ACBT
Number of subjects: 363

Group type: EXPERIMENTAL
Intervention: Acapella plus ACBT
Number of subjects: 363

Group type: COMPARATOR
Intervention: ACBT (control group)
Number of subjects: 363
Study: 36978045

Group type: EXPERIMENTAL
Intervention: i-REBOUND programme receiving physical exercise and support for sustained engagement in physical activity through behavioural change techniques
Number of subjects: 120

Group type: COMPARATOR
Intervention: Behavioural change techniques for physical activity
Number of subjects: 120
Study: 36978066

Group type: EXPERIMENTAL
Intervention: Sitagliptin (part of the TECOS trial)
Number of subjects: 0
Study: 36978071

Group type: EXPERIMENTAL
Intervention: CHW-led CHORD intervention
Number of subjects: 559

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 559
Study: 36978080

Group type: EXPERIMENTAL
Intervention: Epicardial adipose tissue (EAT) thickness measurement
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: NT-proBNP and GLS as mediators
Number of subjects: 1554

Group type: EXPERIMENTAL
Intervention: EAT assessment
Number of subjects: 1554
Study: 36978097

Group type: EXPERIMENTAL
Intervention: Offering three raw carrot batons and three cucumber sticks alongside children's main breakfast food each day for three weeks.
Number of subjects: 351

Group type: COMPARATOR
Intervention: Usual breakfast provided in control nurseries.
Number of subjects: 351

Group type: EXPERIMENTAL
Intervention: Data collection preference by nursery staff.
Number of subjects: 351
Study: 36978099

Group type: EXPERIMENTAL
Intervention: Analgesic therapy for moderate/severe pain
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Multimodal analgesia with opioids
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Opioids alone
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Time-based therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intermittent therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: No therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pain prevalence
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pain intensity
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Pain management improvements
Number of subjects: 63
Study: 36978128

Group type: EXPERIMENTAL
Intervention: 45,X
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 47,XXY
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat and muscle tissues
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X chromosomal genes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: X chromosome number
Number of subjects: 0
Study: 36979637

Group type: EXPERIMENTAL
Intervention: Genetic testing for DAO deficiency
Number of subjects: 0
Study: 36979982

Group type: EXPERIMENTAL
Intervention: Telerehabilitation-Based Structured Home Program
Number of subjects: 43

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 43
Study: 36980529

Group type: EXPERIMENTAL
Intervention: Clinical risk factors used for treatment stratification in the EpSSG RMS 2005 protocol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current EpSSG overarching study for frontline and relapsed rhabdomyosarcoma (FaR-RMS NCT04625907)
Number of subjects: 0
Study: 36981850

Group type: EXPERIMENTAL
Intervention: Cognitive training (speed of processing, memory, reasoning)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 0
Study: 36983145

Group type: EXPERIMENTAL
Intervention: Cognitive Remediation (CR) fully immersive Virtual Reality (VR) recovery-oriented program plus conventional care
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 64
Study: 36987384

Group type: EXPERIMENTAL
Intervention: Synchronous multiple gastric cancer (SMGC)
Number of subjects: 14603

Group type: COMPARATOR
Intervention: Single gastric cancer (GC)
Number of subjects: 14603

Group type: EXPERIMENTAL
Intervention: Advanced gastric cancer (AGC) with SMGC
Number of subjects: 14603
Study: 36987387

Group type: EXPERIMENTAL
Intervention: Intensive CIMT
Number of subjects: 50

Group type: COMPARATOR
Intervention: Distributed CIMT
Number of subjects: 50
Study: 36987440

Group type: EXPERIMENTAL
Intervention: Symptomatic myocarditis (n=17)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Symptomatic no myocarditis (n=17)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Asymptomatic (n=20)
Number of subjects: 54
Study: 36987682

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided percutaneous nerve stimulation (PENS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 70
Study: 36987703

Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 70
Study: 36987836

Group type: EXPERIMENTAL
Intervention: BI 907828
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study: 36987861

Group type: EXPERIMENTAL
Intervention: BBIBP-CorV inactivated SARS-CoV-2 vaccine
Number of subjects: 0
Study: 36987929

Group type: EXPERIMENTAL
Intervention: edoxaban
Number of subjects: 21005

Group type: COMPARATOR
Intervention: warfarin
Number of subjects: 21005

Group type: EXPERIMENTAL
Intervention: hsTnT, NT-proBNP, GDF-15 (serial measurement)
Number of subjects: 21005
Study: 36988304

Group type: EXPERIMENTAL
Intervention: Individual Cognitive Processing Therapy for PTSD
Number of subjects: 223

Group type: COMPARATOR
Intervention: Group Cognitive Processing Therapy for PTSD
Number of subjects: 223
Study: 36988337

Group type: EXPERIMENTAL
Intervention: Implementation of ventilator protocols for low tidal volume ventilation (LTVV) in the ICU.
Number of subjects: 8692

Group type: EXPERIMENTAL
Intervention: Implementation of ventilator protocols for low tidal volume ventilation (LTVV) in the ICU among patients with ARDS.
Number of subjects: 8692
Study: 36988361

Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (ITM) 0.3 mg
Number of subjects: 82

Group type: COMPARATOR
Intervention: Erector spinae plane block (ESPB) with 0.25% bupivacaine
Number of subjects: 82
Study: 36988483

Group type: EXPERIMENTAL
Intervention: Optimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) intervention, details not available
Number of subjects: 0
Study: 36988592

Group type: EXPERIMENTAL
Intervention: Transcatheter arterialization of the deep veins
Number of subjects: 105
Study: 36988594

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously on day 1 and at weeks 2, 6, 14, 22, and 30)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Vedolizumab (300 mg intravenously)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 36988715

Group type: EXPERIMENTAL
Intervention: 80-kVp thin-section pancreatic CT
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Tumor response after neoadjuvant therapy
Number of subjects: 138
Study: 36988757

Group type: EXPERIMENTAL
Intervention: ByCross® atherectomy device
Number of subjects: 39